<DOC>
	<DOCNO>NCT00958009</DOCNO>
	<brief_summary>The purpose trial test Single-Use Autoinjector ) ease use ; b ) multiple domain related subject 's acceptability satisfaction , c ) reliability correct function self-injection Rebif® 44 mcg sc tiw subject relapse multiple sclerosis ( RMS ) .</brief_summary>
	<brief_title>The Multicenter , Open-label , Single-use Autoinjector Convenience Study</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>1 . Male female subject , 1865 year age , inclusive , time informed consent signature 2 . RMS diagnose accord McDonald criterion 3 . Currently receive Rebif® 44mcg sc tiw use manual injection and/or Rebiject II autoinjector great twelve week 4 . Capable selfinjecting use singleuse autoinjector 5 . Be willing able comply study procedure duration trial 6 . Have give write informed consent sign Health Insurance Portability Accountability Act ( HIPAA ) Authorization studyrelated activity carry 7 . Female subject must either pregnant breastfeeding must lack childbearing potential 1 . Have use injectable medication ( i.e . pain ) regular basis week prior Screening throughout duration trial ( administration single injection treatment prophylaxis condition unrelated MS Rebif® therapy ( e.g. , influenza pneumococcus vaccination ) acceptable ) 2 . Have receive MS therapy Rebif® within twelve week prior Screening time trial ( e.g. , disease modify drug , Rebif® New Formulation , combination therapy , immunomodulatory and/or immunosuppressive agent , include limited interferon , glatiramer acetate ( Copolymer I ) , cyclophosphamide , cyclosporine , methotrexate , linomide , azathioprine , mitoxantrone , teriflunomide , laquinimod , cladribine , total lymphoid irradiation , antilymphocyte monoclonal antibody treatment ( e.g . natalizumab , alemtuzumab/Campath , anti CD4 ) , Intravenous immunoglobulin ( IVIg ) , cytokine anticytokine therapy ) telbivudine 3 . Have inadequate liver function , define alanine aminotransferase ( ALT ) &gt; 2.5x upper limit normal ( ULN ) , alkaline phosphatase &gt; 2.5x ULN , total bilirubin &gt; 2.5x ULN 4 . Have inadequate bone marrow reserve , define total white blood cell count &lt; 3.0x 109/L , platelet count &lt; 75x109/L , haemoglobin &lt; 100g/L 5 . Have complete transverse myelitis bilateral optic neuritis 6 . Have history alcohol drug abuse 7 . Have thyroid dysfunction 8 . Have moderate severe renal impairment 9 . Have major medical psychiatric illness opinion investigator create undue risk subject could affect compliance study protocol 10 . Have history seizure adequately control treatment 11 . Have serious acute cardiac disease , uncontrolled dysrhythmias , uncontrolled angina pectoris , cardiomyopathy , uncontrolled congestive heart failure 12 . Have , opinion investigator , visual , physical cognitive impairment would preclude subject selfinjecting singleuse autoinjector 13 . Have know hypersensitivity allergy interferonbeta excipients 14 . Have participate another clinical trial within past thirty day 15 . Are pregnant attempt conceive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>